Pathogenesis Evolution Characteristics and Intervention Strategies for Alternation Between Active and Remission Phases of Inflammatory Bowel Disease：Based on the Theory of "Grease-Turbidity-Heat Toxin"

ZHENG Ting; HUANG Kaiyue; LI Jiayan; WANG Fengyun; TANG Xyudong; LYU Lin

doi:10.13288/j.11-2166/r.2026.15.014

您当前的位置：

首页 >

文章列表页 >

Pathogenesis Evolution Characteristics and Intervention Strategies for Alternation Between Active and Remission Phases of Inflammatory Bowel Disease：Based on the Theory of "Grease-Turbidity-Heat Toxin"

更新时间：2026-08-05

- Pathogenesis Evolution Characteristics and Intervention Strategies for Alternation Between Active and Remission Phases of Inflammatory Bowel Disease：Based on the Theory of "Grease-Turbidity-Heat Toxin"
- Journal of Traditional Chinese Medicine Vol. 67, Issue 15, Pages: 1664-1668(2026)
- 作者机构：
  
  1.中国中医科学院西苑医院脾胃病研究所，北京市海淀区西苑操场1号，100091
  2.中国中医科学院研究生院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2026.15.014
  CLC：
- Received：19 January 2026，
  
  Revised：2026-05-08，
  
  Accepted：23 March 2026，
  
  Online First：03 August 2026，
  
  Published：02 August 2026
- 稿件说明：
移动端阅览
正婷,黄开月,李嘉言等.炎症性肠病活动-缓解交替的“膏-浊-热毒”病机演变特点及干预策略[J].中医杂志,2026,67(15):1664-1668.

ZHENG Ting,HUANG Kaiyue,LI Jiayan,et al.Pathogenesis Evolution Characteristics and Intervention Strategies for Alternation Between Active and Remission Phases of Inflammatory Bowel Disease：Based on the Theory of "Grease-Turbidity-Heat Toxin"[J].Journal of Traditional Chinese Medicine,2026,67(15):1664-1668.
正婷,黄开月,李嘉言等.炎症性肠病活动-缓解交替的“膏-浊-热毒”病机演变特点及干预策略[J].中医杂志,2026,67(15):1664-1668. DOI： 10.13288/j.11-2166/r.2026.15.014.

ZHENG Ting,HUANG Kaiyue,LI Jiayan,et al.Pathogenesis Evolution Characteristics and Intervention Strategies for Alternation Between Active and Remission Phases of Inflammatory Bowel Disease：Based on the Theory of "Grease-Turbidity-Heat Toxin"[J].Journal of Traditional Chinese Medicine,2026,67(15):1664-1668. DOI： 10.13288/j.11-2166/r.2026.15.014.

摘要

以“膏-浊-热毒”为框架，阐释炎症性肠病（IBD）活动-缓解交替的病机演变规律。认为IBD活动期呈膏浊内蕴、蕴郁化热、热盛酿毒的递进爆发过程，缓解期现热毒势戢、气阴耗伤、余浊伏匿、正虚邪恋的状态。据此确立分期论治，动态截断干预策略，即活动期遵循畅、清、解序贯祛邪，初期以畅调气机、健脾化浊为法，予痛泻要方合参苓白术散畅机健脾；中期立清热化湿、分消走泄之策，予葛根芩连汤合半夏泻心汤清消湿热；后期行解毒敛疡、凉血宁络之法，予白头翁汤、芍药汤合犀角地黄汤解毒凉血；缓解期秉持扶、固、透安内清源，以四神丸合四君子汤扶正透邪。

Abstract

Based on the theoretical framework of "grease-turbidity-heat toxin"， this paper elucidates the patholo-gical evolution pattern underlying the alternation between active and remission phases of inflammatory bowel disease （IBD）. It is proposed that the active phase of IBD represents a progressive and explosive process characterized by internal accumulation of grease turbidity，

constraint transforming into heat， and exuberant heat generating toxin. During the remission phase， the pathogenic process manifests as subsidence of heat toxin， depletion of

and

yin

， latent retention of residual turbidity， and a state of coexistence between deficiency of healthy

and lingering pathogenic factors. Accordingly， a staged therapeutic strategy with dynamic intervention and targeted modulation has been established. During the active phase， treatment follows the sequential principle of unblocking， clearing， and resolving pathogenic factors. In the early stage， the therapeutic approach focuses on regulating

movement， fortifying the spleen， and resolving turbidity， using

Tongxie Essential Formula

（痛泻要方） and

Shenling Baizhu Powder

（参苓白术散） to regulate

and fortify spleen. In the middle stage， the strategy emphasizes clearing heat， eliminating dampness， and dispersing pathogenic accumulation through downward and outward pathways， and

Gegen Qinlian Decoction

（葛根芩连汤） combined with

Banxia Xiexin Decoction

（半夏泻心汤） is used to clear and resolve damp-heat. In the late stage， treatment aims to resolve toxin， restrain sore， cool blood， and stabilize collaterals， using

Baitouweng Decoction

（白头翁汤），

Shaoyao Decoction

（芍药汤）， and

Xijiao Dihuang Decoction

（犀角地黄汤） to eliminate toxins and cool blood. During the remission phase， the principle of reinforcing， consolidating， and penetrating is adopted to restore internal balance and clear the source， using

Sishen Pills

（四神丸） and

Sijunzi Decoction

（四君子汤） to reinforce healthy

and venting pathogens.

关键词

Keywords

references

Bruner L P ， White A M ， Proksell S . Inflammatory bowel disease ［J］. Prim Care ， 2023 ， 50 （ 3 ）： 411 - 427 .

Yang H ， Qian J . Epidemiological research， burden， and clinical advances of inflammatory bowel disease in China ［J］. Chin Med J ， 2024 ， 137 （ 9 ）： 1009 - 1011 .

苏晓兰，国嵩，张涛，等 . 炎症性肠病诊治现状及中医药治疗特色与优势［J］. 北京中医药， 2020 ， 39 （ 3 ）： 211 - 215 .

李军祥，沈洪，毛堂友，等 . 炎症性肠病中医药诊疗及机制研究现状［J］. 中医杂志， 2026 ， 67 （ 1 ）： 103 - 110 .

李玉莹，杨鑫敏，钟少琦，等 . 从“膏-浊-热毒”病机演变浅析高甘油三酯血症相关性急性胰腺炎重症化的机制［J］. 北京中医药大学学报， 2024 ， 47 （ 5 ）： 672 - 678 .

邢韵淇，李军祥，张文基，等 . 基于肠道黏液屏障探讨“厚肠理论”的生物学内涵及其在溃疡性结肠炎诊治中的应用［J］. 中国医药导报， 2023 ， 20 （ 5 ）： 128 - 132 .

赵进喜，庞博 . 中医学“浊”的涵义及其临床意义［J］. 中医杂志， 2009 ， 50 （ 7 ）： 581 - 584 .

范逸品，李建鹏，张莹莹，等 . 王永炎从虚气留滞、毒损脑络论治血管性认知障碍经验［J］. 中医杂志， 2025 ， 66 （ 23 ）： 2411 - 2415 .

于智敏 . “毒”的本义和引申义考辨［J］. 中国中医基础医学杂志， 2005 ， 11 （ 2 ）： 101 - 102 .

仝小林，刘文科 . 论膏浊病［J］. 中医杂志， 2011 ， 52 （ 10 ）： 816 - 818 .

Xie H ， Yu S ， Tang M ， et al . Gut microbiota dysbiosis in inflammatory bowel disease： interaction with intestinal barriers and microbiota-targeted treatment options ［J］. Front Cell Infect Microbiol ， 2025 ， 15 ： 1608025 . DOI： 10.3389/fcimb.2025.1608025 http://dx.doi.org/10.3389/fcimb.2025.1608025 .

王冬，张晓岚 . 内镜在炎症性肠病中的作用［J］. 临床荟萃， 2016 ， 31 （ 8 ）： 852 - 856 .

Tang X ， Huang Y ， Zhu Y ， et al . Immune dysregulation in ulcerative colitis： pathogenic mechanisms and therapeutic strategies of traditional Chinese medicine ［J］. Front Cell Develop Biol ， 2025 ， 13 ： 1610435 . DOI： 10.3389/fcell.2025.1610435 http://dx.doi.org/10.3389/fcell.2025.1610435 .

张惜燕，邢玉瑞，李翠娟，等 . 《黄帝内经》视角下中医毒性理论的内涵与应用［J］. 中医杂志， 2025 ， 66 （ 15 ）： 1517 - 1521 .

Unger L W ， Kaser A . Is IL-6 back in trans signaling for inflammatory bowel disease？［J］. Gastroenterology ， 2021 ， 160 （ 7 ）： 2247 - 2249 .

Velikova T V ， Miteva L ， Stanilov N ， et al . Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer ［J］. World J Gastroenterol ， 2020 ， 26 （ 16 ）： 1912 - 1925 .

王伟，王津迪，宋连强，等 . 缓解期炎症性肠病患者的肠易激综合征样症状的研究进展［J］. 临床消化病杂志， 2024 ， 36 （ 4 ）： 292 - 296 .

陈霞，樊官伟，蒲翔，等 . 基于中性粒细胞胞外诱捕网探讨白及修复溃疡性结肠炎大鼠肠黏膜屏障的作用及机制［J］. 中药新药与临床药理， 2024 ， 35 （ 4 ）： 453 - 460 .

刘位杰，梁敬钰，孙建博，等 . 仙鹤草化学成分及药理作用研究进展［J］. 海峡药学， 2016 ， 28 （ 2 ）： 1 - 7 .

Lichtenstein G R ， Loftus E V ， Afzali A ， et al . ACG Clinical guideline： management of Crohn's disease in adults ［J］. Am J Gastroenterol ， 2025 ， 120 （ 6 ）： 1225 - 1264 .

Rubin D T ， Ananthakrishnan A N ， Siegel C A ， et al . ACG clinical guideline update： ulcerative colitis in adults ［J］. Am J Gastroenterol ， 2025 ， 120 （ 6 ）： 1187 - 1224 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Experience of Professor LIU Shangyi in Treating Acute Mastitis from the Perspective of "Membrane Collaterals"

Construction of a Multimodal AI-Based Integrated Traditional Chinese and Western Medicine Big Data Platform for Inflammatory Bowel Disease with Specialized Disease Cohort

Current Status of Traditional Chinese Medicine Diagnosis and Treatment of Inflammatory Bowel Disease and the Research on Mechanism

Exploration on the Syndrome Differentiation and Treatment Strategies for Inflammation-Cancer Transformation in Inflammatory Bowel Disease Based on the Theory of Cold Qi-Induced Accumulation

Clinical Experience of Professor QIN Danping in Treating Inflammatory Bowel Disease by Internal and External Treatment with Traditional Chinese Medicine

Related Author

刘尚义

WANG Ling

WEI Rong

LIU Xiao

DENG Dongyang

ZHANG Fang

SHEN Hong

ZHU Lei

Related Institution

Shandong Women's University

The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

The First Clinical Medical College of Guizhou University of Traditional Chinese Medicine

Jiangsu Province Hospital of Chinese Medicine/Affiliated Hospital of Nanjing University of Chinese Medicine

Institute of Gastroenterology，Xiyuan Hospital，China Academy of Chinese Medical Sciences

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰